nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—BMPR1B—prostate cancer	0.112	0.253	CbGaD
Vandetanib—IRAK4—prostate cancer	0.112	0.253	CbGaD
Vandetanib—ERBB3—prostate cancer	0.0515	0.116	CbGaD
Vandetanib—PDGFRB—prostate cancer	0.0426	0.0959	CbGaD
Vandetanib—SRC—prostate cancer	0.0344	0.0774	CbGaD
Vandetanib—KDR—prostate cancer	0.0323	0.0727	CbGaD
Vandetanib—ORM1—Abiraterone—prostate cancer	0.0283	0.108	CbGbCtD
Vandetanib—VEGFA—prostate cancer	0.0274	0.0616	CbGaD
Vandetanib—EGFR—Docetaxel—prostate cancer	0.026	0.0991	CbGbCtD
Vandetanib—ABCC1—Abiraterone—prostate cancer	0.0258	0.0985	CbGbCtD
Vandetanib—EGFR—prostate cancer	0.0231	0.052	CbGaD
Vandetanib—ABCG2—Cabazitaxel—prostate cancer	0.0128	0.0488	CbGbCtD
Vandetanib—ABCG2—Estrone—prostate cancer	0.0125	0.0477	CbGbCtD
Vandetanib—ABCC1—Conjugated Estrogens—prostate cancer	0.0122	0.0466	CbGbCtD
Vandetanib—ALB—Abiraterone—prostate cancer	0.0119	0.0455	CbGbCtD
Vandetanib—ABCC1—Mitoxantrone—prostate cancer	0.0111	0.0424	CbGbCtD
Vandetanib—ABCC1—Epirubicin—prostate cancer	0.00899	0.0343	CbGbCtD
Vandetanib—ALB—Estrone—prostate cancer	0.00861	0.0329	CbGbCtD
Vandetanib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00858	0.0327	CbGbCtD
Vandetanib—CYP3A4—prostate cancer	0.00844	0.019	CbGaD
Vandetanib—ABCG2—Conjugated Estrogens—prostate cancer	0.00817	0.0312	CbGbCtD
Vandetanib—ABCG2—Mitoxantrone—prostate cancer	0.00743	0.0283	CbGbCtD
Vandetanib—ABCG2—Estradiol—prostate cancer	0.00718	0.0274	CbGbCtD
Vandetanib—ABCC1—Etoposide—prostate cancer	0.007	0.0267	CbGbCtD
Vandetanib—ABCC1—Docetaxel—prostate cancer	0.00641	0.0244	CbGbCtD
Vandetanib—ALB—Estradiol—prostate cancer	0.00495	0.0189	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—prostate cancer	0.00478	0.0182	CbGbCtD
Vandetanib—ABCG2—Etoposide—prostate cancer	0.00469	0.0179	CbGbCtD
Vandetanib—CYP3A4—Bicalutamide—prostate cancer	0.00451	0.0172	CbGbCtD
Vandetanib—ABCG2—Docetaxel—prostate cancer	0.00429	0.0164	CbGbCtD
Vandetanib—ALB—Prednisone—prostate cancer	0.00425	0.0162	CbGbCtD
Vandetanib—CYP3A4—Estramustine—prostate cancer	0.00419	0.016	CbGbCtD
Vandetanib—CYP3A4—Abiraterone—prostate cancer	0.00373	0.0142	CbGbCtD
Vandetanib—CYP3A4—Flutamide—prostate cancer	0.00373	0.0142	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—prostate cancer	0.0032	0.0122	CbGbCtD
Vandetanib—CYP3A4—Cabazitaxel—prostate cancer	0.00276	0.0105	CbGbCtD
Vandetanib—CYP3A4—Estrone—prostate cancer	0.0027	0.0103	CbGbCtD
Vandetanib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00241	0.00918	CbGbCtD
Vandetanib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00177	0.00674	CbGbCtD
Vandetanib—CYP3A4—Mitoxantrone—prostate cancer	0.00161	0.00612	CbGbCtD
Vandetanib—CYP3A4—Estradiol—prostate cancer	0.00155	0.00592	CbGbCtD
Vandetanib—FMO3—urine—prostate cancer	0.00142	0.024	CbGeAlD
Vandetanib—CYP3A4—Prednisone—prostate cancer	0.00133	0.00509	CbGbCtD
Vandetanib—CYP3A4—Etoposide—prostate cancer	0.00101	0.00386	CbGbCtD
Vandetanib—PTK6—prostate gland—prostate cancer	0.001	0.0169	CbGeAlD
Vandetanib—CYP3A4—Docetaxel—prostate cancer	0.000926	0.00353	CbGbCtD
Vandetanib—EPHA6—prostate gland—prostate cancer	0.000834	0.0141	CbGeAlD
Vandetanib—EPHA5—prostate gland—prostate cancer	0.000773	0.0131	CbGeAlD
Vandetanib—BMPR1B—prostate gland—prostate cancer	0.000758	0.0128	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—prostate cancer	0.00069	0.00263	CbGbCtD
Vandetanib—PTK6—renal system—prostate cancer	0.000681	0.0116	CbGeAlD
Vandetanib—PTK6—urethra—prostate cancer	0.000669	0.0113	CbGeAlD
Vandetanib—STK35—prostate gland—prostate cancer	0.000644	0.0109	CbGeAlD
Vandetanib—ABL2—prostate gland—prostate cancer	0.000628	0.0106	CbGeAlD
Vandetanib—EGFR—prostate gland—prostate cancer	0.000613	0.0104	CbGeAlD
Vandetanib—FLT4—prostate gland—prostate cancer	0.000597	0.0101	CbGeAlD
Vandetanib—RIPK2—prostate gland—prostate cancer	0.000594	0.0101	CbGeAlD
Vandetanib—VEGFA—prostate gland—prostate cancer	0.000592	0.01	CbGeAlD
Vandetanib—FMO1—prostate gland—prostate cancer	0.000589	0.00999	CbGeAlD
Vandetanib—IRAK4—prostate gland—prostate cancer	0.00058	0.00983	CbGeAlD
Vandetanib—ERBB3—prostate gland—prostate cancer	0.000569	0.00964	CbGeAlD
Vandetanib—BMPR1B—epithelium—prostate cancer	0.000557	0.00944	CbGeAlD
Vandetanib—MKNK1—prostate gland—prostate cancer	0.000534	0.00905	CbGeAlD
Vandetanib—LCK—prostate gland—prostate cancer	0.000527	0.00894	CbGeAlD
Vandetanib—FGR—prostate gland—prostate cancer	0.000527	0.00894	CbGeAlD
Vandetanib—RET—prostate gland—prostate cancer	0.000527	0.00894	CbGeAlD
Vandetanib—AXL—prostate gland—prostate cancer	0.000525	0.0089	CbGeAlD
Vandetanib—FMO3—prostate gland—prostate cancer	0.000509	0.00863	CbGeAlD
Vandetanib—SLK—prostate gland—prostate cancer	0.000506	0.00857	CbGeAlD
Vandetanib—RIPK2—seminal vesicle—prostate cancer	0.000502	0.00852	CbGeAlD
Vandetanib—FYN—prostate gland—prostate cancer	0.000492	0.00833	CbGeAlD
Vandetanib—IRAK4—seminal vesicle—prostate cancer	0.000491	0.00832	CbGeAlD
Vandetanib—TEK—prostate gland—prostate cancer	0.00048	0.00814	CbGeAlD
Vandetanib—MAP4K5—prostate gland—prostate cancer	0.00048	0.00814	CbGeAlD
Vandetanib—LTK—testis—prostate cancer	0.000459	0.00779	CbGeAlD
Vandetanib—EPHB6—prostate gland—prostate cancer	0.000459	0.00778	CbGeAlD
Vandetanib—FGR—seminal vesicle—prostate cancer	0.000446	0.00756	CbGeAlD
Vandetanib—YES1—prostate gland—prostate cancer	0.000444	0.00752	CbGeAlD
Vandetanib—EPHA8—testis—prostate cancer	0.00044	0.00747	CbGeAlD
Vandetanib—STK10—prostate gland—prostate cancer	0.00044	0.00745	CbGeAlD
Vandetanib—FLT4—epithelium—prostate cancer	0.000439	0.00744	CbGeAlD
Vandetanib—RIPK2—epithelium—prostate cancer	0.000436	0.0074	CbGeAlD
Vandetanib—SLK—seminal vesicle—prostate cancer	0.000428	0.00725	CbGeAlD
Vandetanib—SRC—prostate gland—prostate cancer	0.000427	0.00723	CbGeAlD
Vandetanib—PLK4—bone marrow—prostate cancer	0.000424	0.00719	CbGeAlD
Vandetanib—ERBB3—epithelium—prostate cancer	0.000418	0.00708	CbGeAlD
Vandetanib—FYN—seminal vesicle—prostate cancer	0.000416	0.00705	CbGeAlD
Vandetanib—MAP4K5—seminal vesicle—prostate cancer	0.000406	0.00689	CbGeAlD
Vandetanib—FMO1—renal system—prostate cancer	0.000402	0.00681	CbGeAlD
Vandetanib—RIPK2—urethra—prostate cancer	0.000398	0.00674	CbGeAlD
Vandetanib—VEGFA—urethra—prostate cancer	0.000397	0.00672	CbGeAlD
Vandetanib—FMO1—urethra—prostate cancer	0.000394	0.00669	CbGeAlD
Vandetanib—MAP2K5—prostate gland—prostate cancer	0.000393	0.00665	CbGeAlD
Vandetanib—KDR—prostate gland—prostate cancer	0.000393	0.00665	CbGeAlD
Vandetanib—IRAK4—urethra—prostate cancer	0.000388	0.00658	CbGeAlD
Vandetanib—EPHB6—seminal vesicle—prostate cancer	0.000388	0.00658	CbGeAlD
Vandetanib—ERBB3—renal system—prostate cancer	0.000388	0.00657	CbGeAlD
Vandetanib—RET—epithelium—prostate cancer	0.000387	0.00657	CbGeAlD
Vandetanib—Bosutinib—PRKCQ—prostate cancer	0.000382	0.0931	CrCbGaD
Vandetanib—Bosutinib—EPHB2—prostate cancer	0.000382	0.0931	CrCbGaD
Vandetanib—YES1—seminal vesicle—prostate cancer	0.000375	0.00636	CbGeAlD
Vandetanib—CYP3A4—urine—prostate cancer	0.000371	0.00628	CbGeAlD
Vandetanib—EPHA6—testis—prostate cancer	0.000367	0.00623	CbGeAlD
Vandetanib—PLK4—testis—prostate cancer	0.000363	0.00615	CbGeAlD
Vandetanib—RET—renal system—prostate cancer	0.000359	0.00609	CbGeAlD
Vandetanib—MKNK1—urethra—prostate cancer	0.000357	0.00606	CbGeAlD
Vandetanib—FGR—urethra—prostate cancer	0.000353	0.00598	CbGeAlD
Vandetanib—LCK—urethra—prostate cancer	0.000353	0.00598	CbGeAlD
Vandetanib—TEK—epithelium—prostate cancer	0.000353	0.00598	CbGeAlD
Vandetanib—AXL—urethra—prostate cancer	0.000352	0.00596	CbGeAlD
Vandetanib—Gefitinib—IRAK4—prostate cancer	0.000346	0.0843	CrCbGaD
Vandetanib—TYRO3—testis—prostate cancer	0.000341	0.00578	CbGeAlD
Vandetanib—Afatinib—ERBB2—prostate cancer	0.000341	0.083	CrCbGaD
Vandetanib—Bosutinib—IRAK4—prostate cancer	0.000341	0.083	CrCbGaD
Vandetanib—PDGFRB—prostate gland—prostate cancer	0.00034	0.00576	CbGeAlD
Vandetanib—FLT3—bone marrow—prostate cancer	0.000339	0.00574	CbGeAlD
Vandetanib—SLK—urethra—prostate cancer	0.000338	0.00574	CbGeAlD
Vandetanib—BLK—lymph node—prostate cancer	0.000337	0.00571	CbGeAlD
Vandetanib—FYN—renal system—prostate cancer	0.000335	0.00568	CbGeAlD
Vandetanib—BMPR1B—testis—prostate cancer	0.000334	0.00566	CbGeAlD
Vandetanib—MAP3K19—testis—prostate cancer	0.000334	0.00566	CbGeAlD
Vandetanib—LTK—lymph node—prostate cancer	0.000333	0.00564	CbGeAlD
Vandetanib—MAP2K5—seminal vesicle—prostate cancer	0.000332	0.00563	CbGeAlD
Vandetanib—KDR—seminal vesicle—prostate cancer	0.000332	0.00563	CbGeAlD
Vandetanib—FYN—urethra—prostate cancer	0.000329	0.00558	CbGeAlD
Vandetanib—TEK—renal system—prostate cancer	0.000327	0.00555	CbGeAlD
Vandetanib—MAP4K5—urethra—prostate cancer	0.000322	0.00545	CbGeAlD
Vandetanib—TEK—urethra—prostate cancer	0.000322	0.00545	CbGeAlD
Vandetanib—ORM1—prostate gland—prostate cancer	0.000319	0.0054	CbGeAlD
Vandetanib—SRC—epithelium—prostate cancer	0.000314	0.00532	CbGeAlD
Vandetanib—FLT4—bone marrow—prostate cancer	0.000308	0.00522	CbGeAlD
Vandetanib—EPHB6—urethra—prostate cancer	0.000307	0.00521	CbGeAlD
Vandetanib—RIPK2—bone marrow—prostate cancer	0.000306	0.00519	CbGeAlD
Vandetanib—VEGFA—bone marrow—prostate cancer	0.000305	0.00517	CbGeAlD
Vandetanib—ABL1—prostate gland—prostate cancer	0.000303	0.00513	CbGeAlD
Vandetanib—YES1—renal system—prostate cancer	0.000302	0.00513	CbGeAlD
Vandetanib—STK10—renal system—prostate cancer	0.0003	0.00508	CbGeAlD
Vandetanib—IRAK4—bone marrow—prostate cancer	0.000299	0.00507	CbGeAlD
Vandetanib—YES1—urethra—prostate cancer	0.000297	0.00503	CbGeAlD
Vandetanib—SRC—renal system—prostate cancer	0.000291	0.00493	CbGeAlD
Vandetanib—FLT3—testis—prostate cancer	0.00029	0.00491	CbGeAlD
Vandetanib—KDR—epithelium—prostate cancer	0.000288	0.00489	CbGeAlD
Vandetanib—PDGFRB—seminal vesicle—prostate cancer	0.000287	0.00487	CbGeAlD
Vandetanib—STK35—testis—prostate cancer	0.000284	0.00481	CbGeAlD
Vandetanib—ABL2—testis—prostate cancer	0.000277	0.00469	CbGeAlD
Vandetanib—MKNK1—bone marrow—prostate cancer	0.000275	0.00466	CbGeAlD
Vandetanib—LCK—bone marrow—prostate cancer	0.000272	0.00461	CbGeAlD
Vandetanib—FGR—bone marrow—prostate cancer	0.000272	0.00461	CbGeAlD
Vandetanib—EGFR—testis—prostate cancer	0.00027	0.00458	CbGeAlD
Vandetanib—KDR—renal system—prostate cancer	0.000268	0.00454	CbGeAlD
Vandetanib—FLT4—testis—prostate cancer	0.000263	0.00446	CbGeAlD
Vandetanib—PLK4—lymph node—prostate cancer	0.000263	0.00446	CbGeAlD
Vandetanib—KDR—urethra—prostate cancer	0.000263	0.00446	CbGeAlD
Vandetanib—MAP2K5—urethra—prostate cancer	0.000263	0.00446	CbGeAlD
Vandetanib—RIPK2—testis—prostate cancer	0.000262	0.00444	CbGeAlD
Vandetanib—VEGFA—testis—prostate cancer	0.000261	0.00442	CbGeAlD
Vandetanib—SLK—bone marrow—prostate cancer	0.000261	0.00442	CbGeAlD
Vandetanib—Bosutinib—MAP3K7—prostate cancer	0.000258	0.0629	CrCbGaD
Vandetanib—ABL1—seminal vesicle—prostate cancer	0.000256	0.00434	CbGeAlD
Vandetanib—IRAK4—testis—prostate cancer	0.000256	0.00433	CbGeAlD
Vandetanib—FYN—bone marrow—prostate cancer	0.000253	0.00429	CbGeAlD
Vandetanib—ERBB3—testis—prostate cancer	0.00025	0.00425	CbGeAlD
Vandetanib—PDGFRB—epithelium—prostate cancer	0.00025	0.00423	CbGeAlD
Vandetanib—MAP4K5—bone marrow—prostate cancer	0.000248	0.0042	CbGeAlD
Vandetanib—BMPR1B—lymph node—prostate cancer	0.000242	0.0041	CbGeAlD
Vandetanib—MKNK1—testis—prostate cancer	0.000235	0.00399	CbGeAlD
Vandetanib—FGR—testis—prostate cancer	0.000232	0.00394	CbGeAlD
Vandetanib—RET—testis—prostate cancer	0.000232	0.00394	CbGeAlD
Vandetanib—LCK—testis—prostate cancer	0.000232	0.00394	CbGeAlD
Vandetanib—PDGFRB—renal system—prostate cancer	0.000232	0.00393	CbGeAlD
Vandetanib—MKNK1—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000232	0.101	CbGdCrCtD
Vandetanib—AXL—testis—prostate cancer	0.000231	0.00392	CbGeAlD
Vandetanib—ABCC1—prostate gland—prostate cancer	0.000231	0.00391	CbGeAlD
Vandetanib—YES1—bone marrow—prostate cancer	0.000229	0.00388	CbGeAlD
Vandetanib—PDGFRB—urethra—prostate cancer	0.000227	0.00386	CbGeAlD
Vandetanib—STK10—bone marrow—prostate cancer	0.000227	0.00384	CbGeAlD
Vandetanib—FMO3—testis—prostate cancer	0.000224	0.0038	CbGeAlD
Vandetanib—SLK—testis—prostate cancer	0.000223	0.00378	CbGeAlD
Vandetanib—Bosutinib—MAP2K1—prostate cancer	0.000219	0.0535	CrCbGaD
Vandetanib—FYN—testis—prostate cancer	0.000217	0.00367	CbGeAlD
Vandetanib—TEK—testis—prostate cancer	0.000212	0.00359	CbGeAlD
Vandetanib—MAP4K5—testis—prostate cancer	0.000212	0.00359	CbGeAlD
Vandetanib—FLT3—lymph node—prostate cancer	0.00021	0.00356	CbGeAlD
Vandetanib—ABL1—renal system—prostate cancer	0.000206	0.0035	CbGeAlD
Vandetanib—STK35—lymph node—prostate cancer	0.000206	0.00349	CbGeAlD
Vandetanib—ABL1—urethra—prostate cancer	0.000203	0.00344	CbGeAlD
Vandetanib—KDR—bone marrow—prostate cancer	0.000202	0.00343	CbGeAlD
Vandetanib—EPHB6—testis—prostate cancer	0.000202	0.00343	CbGeAlD
Vandetanib—ABL2—lymph node—prostate cancer	0.0002	0.0034	CbGeAlD
Vandetanib—MKNK1—Estradiol—Estramustine—prostate cancer	0.000197	0.0858	CbGdCrCtD
Vandetanib—EGFR—lymph node—prostate cancer	0.000196	0.00332	CbGeAlD
Vandetanib—YES1—testis—prostate cancer	0.000195	0.00331	CbGeAlD
Vandetanib—ABCC1—seminal vesicle—prostate cancer	0.000195	0.00331	CbGeAlD
Vandetanib—STK10—testis—prostate cancer	0.000194	0.00328	CbGeAlD
Vandetanib—ABCG2—prostate gland—prostate cancer	0.000191	0.00324	CbGeAlD
Vandetanib—FLT4—lymph node—prostate cancer	0.000191	0.00323	CbGeAlD
Vandetanib—RIPK2—lymph node—prostate cancer	0.00019	0.00322	CbGeAlD
Vandetanib—VEGFA—lymph node—prostate cancer	0.000189	0.00321	CbGeAlD
Vandetanib—FMO1—lymph node—prostate cancer	0.000188	0.00319	CbGeAlD
Vandetanib—SRC—testis—prostate cancer	0.000188	0.00319	CbGeAlD
Vandetanib—IRAK4—lymph node—prostate cancer	0.000185	0.00314	CbGeAlD
Vandetanib—ERBB3—lymph node—prostate cancer	0.000182	0.00308	CbGeAlD
Vandetanib—Gefitinib—CHEK2—prostate cancer	0.000178	0.0434	CrCbGaD
Vandetanib—Bosutinib—CHEK2—prostate cancer	0.000175	0.0427	CrCbGaD
Vandetanib—PDGFRB—bone marrow—prostate cancer	0.000175	0.00297	CbGeAlD
Vandetanib—KDR—testis—prostate cancer	0.000173	0.00293	CbGeAlD
Vandetanib—MAP2K5—testis—prostate cancer	0.000173	0.00293	CbGeAlD
Vandetanib—MKNK1—lymph node—prostate cancer	0.00017	0.00289	CbGeAlD
Vandetanib—RET—lymph node—prostate cancer	0.000168	0.00285	CbGeAlD
Vandetanib—LCK—lymph node—prostate cancer	0.000168	0.00285	CbGeAlD
Vandetanib—FGR—lymph node—prostate cancer	0.000168	0.00285	CbGeAlD
Vandetanib—AXL—lymph node—prostate cancer	0.000168	0.00284	CbGeAlD
Vandetanib—ORM1—bone marrow—prostate cancer	0.000164	0.00278	CbGeAlD
Vandetanib—FMO3—lymph node—prostate cancer	0.000163	0.00276	CbGeAlD
Vandetanib—ABCG2—seminal vesicle—prostate cancer	0.000162	0.00274	CbGeAlD
Vandetanib—SLK—lymph node—prostate cancer	0.000161	0.00274	CbGeAlD
Vandetanib—Afatinib—EGFR—prostate cancer	0.000161	0.0392	CrCbGaD
Vandetanib—Gefitinib—ERBB3—prostate cancer	0.000159	0.0387	CrCbGaD
Vandetanib—FYN—lymph node—prostate cancer	0.000157	0.00266	CbGeAlD
Vandetanib—MKNK1—Estradiol—Estrone—prostate cancer	0.000156	0.0681	CbGdCrCtD
Vandetanib—Bosutinib—ERBB3—prostate cancer	0.000156	0.0381	CrCbGaD
Vandetanib—ABL1—bone marrow—prostate cancer	0.000156	0.00265	CbGeAlD
Vandetanib—ABCC1—urethra—prostate cancer	0.000154	0.00262	CbGeAlD
Vandetanib—MAP4K5—lymph node—prostate cancer	0.000153	0.0026	CbGeAlD
Vandetanib—TEK—lymph node—prostate cancer	0.000153	0.0026	CbGeAlD
Vandetanib—PDGFRB—testis—prostate cancer	0.00015	0.00254	CbGeAlD
Vandetanib—EPHB6—lymph node—prostate cancer	0.000147	0.00248	CbGeAlD
Vandetanib—YES1—lymph node—prostate cancer	0.000142	0.0024	CbGeAlD
Vandetanib—STK10—lymph node—prostate cancer	0.00014	0.00238	CbGeAlD
Vandetanib—MKNK1—Estradiol—Conjugated Estrogens—prostate cancer	0.000138	0.06	CbGdCrCtD
Vandetanib—SRC—lymph node—prostate cancer	0.000136	0.00231	CbGeAlD
Vandetanib—ABL1—testis—prostate cancer	0.000133	0.00226	CbGeAlD
Vandetanib—VEGFA—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000133	0.0579	CbGdCrCtD
Vandetanib—ERBB3—Podofilox—Etoposide—prostate cancer	0.000131	0.0571	CbGdCrCtD
Vandetanib—Bosutinib—PDGFRB—prostate cancer	0.000129	0.0315	CrCbGaD
Vandetanib—ABCG2—urethra—prostate cancer	0.000128	0.00217	CbGeAlD
Vandetanib—MAP2K5—lymph node—prostate cancer	0.000125	0.00212	CbGeAlD
Vandetanib—KDR—lymph node—prostate cancer	0.000125	0.00212	CbGeAlD
Vandetanib—ALB—testis—prostate cancer	0.000123	0.00209	CbGeAlD
Vandetanib—Erlotinib—CYP1B1—prostate cancer	0.000121	0.0294	CrCbGaD
Vandetanib—MKNK1—Estradiol—Ethinyl Estradiol—prostate cancer	0.000116	0.0504	CbGdCrCtD
Vandetanib—PLK4—Fulvestrant—Estradiol—prostate cancer	0.000114	0.0497	CbGdCrCtD
Vandetanib—Erlotinib—EGFR—prostate cancer	0.000114	0.0277	CrCbGaD
Vandetanib—VEGFA—Estradiol—Estramustine—prostate cancer	0.000113	0.0493	CbGdCrCtD
Vandetanib—PDGFRB—lymph node—prostate cancer	0.000108	0.00184	CbGeAlD
Vandetanib—Bosutinib—SRC—prostate cancer	0.000104	0.0254	CrCbGaD
Vandetanib—ORM1—lymph node—prostate cancer	0.000102	0.00173	CbGeAlD
Vandetanib—ABCC1—testis—prostate cancer	0.000102	0.00172	CbGeAlD
Vandetanib—PLK4—Teniposide—Etoposide—prostate cancer	0.000101	0.0438	CbGdCrCtD
Vandetanib—ABCG2—bone marrow—prostate cancer	9.84e-05	0.00167	CbGeAlD
Vandetanib—ABL1—lymph node—prostate cancer	9.67e-05	0.00164	CbGeAlD
Vandetanib—Erlotinib—CYP3A5—prostate cancer	9.6e-05	0.0234	CrCbGaD
Vandetanib—CYP3A4—renal system—prostate cancer	9.07e-05	0.00154	CbGeAlD
Vandetanib—VEGFA—Estradiol—Estrone—prostate cancer	8.98e-05	0.0391	CbGdCrCtD
Vandetanib—ALB—lymph node—prostate cancer	8.92e-05	0.00151	CbGeAlD
Vandetanib—ABCG2—testis—prostate cancer	8.41e-05	0.00143	CbGeAlD
Vandetanib—ABL1—Levorphanol—Estrone—prostate cancer	8.37e-05	0.0365	CbGdCrCtD
Vandetanib—VEGFA—Estradiol—Conjugated Estrogens—prostate cancer	7.91e-05	0.0345	CbGdCrCtD
Vandetanib—ABCC1—lymph node—prostate cancer	7.37e-05	0.00125	CbGeAlD
Vandetanib—Gefitinib—EGFR—prostate cancer	7.12e-05	0.0174	CrCbGaD
Vandetanib—Bosutinib—EGFR—prostate cancer	7.01e-05	0.0171	CrCbGaD
Vandetanib—VEGFA—Estradiol—Ethinyl Estradiol—prostate cancer	6.64e-05	0.029	CbGdCrCtD
Vandetanib—Erlotinib—CYP1A1—prostate cancer	6.51e-05	0.0159	CrCbGaD
Vandetanib—ABL1—Levorphanol—Estradiol—prostate cancer	6.34e-05	0.0276	CbGdCrCtD
Vandetanib—ABCG2—lymph node—prostate cancer	6.1e-05	0.00103	CbGeAlD
Vandetanib—Gefitinib—CYP3A5—prostate cancer	6.01e-05	0.0146	CrCbGaD
Vandetanib—PLK4—Idarubicin—Epirubicin—prostate cancer	5.24e-05	0.0228	CbGdCrCtD
Vandetanib—PLK4—Doxorubicin—Epirubicin—prostate cancer	5.24e-05	0.0228	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Doxorubicin—prostate cancer	4.85e-05	0.0211	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—prostate cancer	4.85e-05	0.0211	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—prostate cancer	4.41e-05	0.0192	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—prostate cancer	4.41e-05	0.0192	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—prostate cancer	4.41e-05	0.0192	CbGdCrCtD
Vandetanib—Erlotinib—CYP3A4—prostate cancer	4.15e-05	0.0101	CrCbGaD
Vandetanib—Gefitinib—CYP2C19—prostate cancer	4.09e-05	0.00997	CrCbGaD
Vandetanib—ABL1—Epirubicin—Doxorubicin—prostate cancer	4.08e-05	0.0178	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—prostate cancer	4.08e-05	0.0178	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—prostate cancer	4.08e-05	0.0178	CbGdCrCtD
Vandetanib—Gefitinib—CYP1A1—prostate cancer	4.07e-05	0.00993	CrCbGaD
Vandetanib—Gefitinib—CYP3A4—prostate cancer	2.6e-05	0.00634	CrCbGaD
Vandetanib—Bosutinib—CYP3A4—prostate cancer	2.56e-05	0.00624	CrCbGaD
Vandetanib—Pain—Etoposide—prostate cancer	2.53e-05	0.000233	CcSEcCtD
Vandetanib—Constipation—Etoposide—prostate cancer	2.53e-05	0.000233	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—prostate cancer	2.52e-05	0.000233	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—prostate cancer	2.52e-05	0.000233	CcSEcCtD
Vandetanib—Dizziness—Estradiol—prostate cancer	2.52e-05	0.000232	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—prostate cancer	2.52e-05	0.000232	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—prostate cancer	2.52e-05	0.000232	CcSEcCtD
Vandetanib—Hypertension—Capecitabine—prostate cancer	2.51e-05	0.000232	CcSEcCtD
Vandetanib—Dry mouth—Docetaxel—prostate cancer	2.5e-05	0.000231	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—prostate cancer	2.5e-05	0.000231	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—prostate cancer	2.49e-05	0.00023	CcSEcCtD
Vandetanib—Chest pain—Capecitabine—prostate cancer	2.48e-05	0.000229	CcSEcCtD
Vandetanib—Arthralgia—Capecitabine—prostate cancer	2.48e-05	0.000229	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—prostate cancer	2.48e-05	0.000228	CcSEcCtD
Vandetanib—Anxiety—Capecitabine—prostate cancer	2.47e-05	0.000228	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	2.46e-05	0.000227	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—prostate cancer	2.46e-05	0.000227	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—prostate cancer	2.46e-05	0.000226	CcSEcCtD
Vandetanib—Oedema—Docetaxel—prostate cancer	2.46e-05	0.000226	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—prostate cancer	2.45e-05	0.000226	CcSEcCtD
Vandetanib—Vision blurred—Prednisone—prostate cancer	2.45e-05	0.000225	CcSEcCtD
Vandetanib—Infection—Docetaxel—prostate cancer	2.44e-05	0.000225	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—prostate cancer	2.44e-05	0.000225	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—prostate cancer	2.44e-05	0.000225	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—prostate cancer	2.43e-05	0.000224	CcSEcCtD
Vandetanib—Diarrhoea—Mitoxantrone—prostate cancer	2.43e-05	0.000224	CcSEcCtD
Vandetanib—Dry mouth—Capecitabine—prostate cancer	2.43e-05	0.000224	CcSEcCtD
Vandetanib—Vomiting—Estradiol—prostate cancer	2.42e-05	0.000223	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—prostate cancer	2.42e-05	0.000223	CcSEcCtD
Vandetanib—Gastrointestinal pain—Etoposide—prostate cancer	2.42e-05	0.000223	CcSEcCtD
Vandetanib—Nervous system disorder—Docetaxel—prostate cancer	2.41e-05	0.000222	CcSEcCtD
Vandetanib—Thrombocytopenia—Docetaxel—prostate cancer	2.4e-05	0.000222	CcSEcCtD
Vandetanib—Rash—Estradiol—prostate cancer	2.4e-05	0.000222	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—prostate cancer	2.4e-05	0.000222	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—prostate cancer	2.4e-05	0.000222	CcSEcCtD
Vandetanib—Dermatitis—Estradiol—prostate cancer	2.4e-05	0.000221	CcSEcCtD
Vandetanib—Headache—Estradiol—prostate cancer	2.39e-05	0.00022	CcSEcCtD
Vandetanib—Skin disorder—Docetaxel—prostate cancer	2.38e-05	0.00022	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	2.38e-05	0.00022	CcSEcCtD
Vandetanib—Oedema—Capecitabine—prostate cancer	2.38e-05	0.000219	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—prostate cancer	2.37e-05	0.000219	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—prostate cancer	2.36e-05	0.000218	CcSEcCtD
Vandetanib—Infection—Capecitabine—prostate cancer	2.36e-05	0.000218	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—prostate cancer	2.34e-05	0.000216	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—prostate cancer	2.34e-05	0.000216	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—prostate cancer	2.34e-05	0.000215	CcSEcCtD
Vandetanib—Abdominal pain—Etoposide—prostate cancer	2.34e-05	0.000215	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—prostate cancer	2.34e-05	0.000215	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—prostate cancer	2.34e-05	0.000215	CcSEcCtD
Vandetanib—Nervous system disorder—Capecitabine—prostate cancer	2.33e-05	0.000215	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—prostate cancer	2.33e-05	0.000215	CcSEcCtD
Vandetanib—Thrombocytopenia—Capecitabine—prostate cancer	2.33e-05	0.000215	CcSEcCtD
Vandetanib—Skin disorder—Capecitabine—prostate cancer	2.31e-05	0.000213	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—prostate cancer	2.3e-05	0.000212	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—prostate cancer	2.29e-05	0.000211	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—prostate cancer	2.29e-05	0.000211	CcSEcCtD
Vandetanib—Loss of consciousness—Prednisone—prostate cancer	2.28e-05	0.00021	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—prostate cancer	2.27e-05	0.00021	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—prostate cancer	2.27e-05	0.000209	CcSEcCtD
Vandetanib—Nausea—Estradiol—prostate cancer	2.26e-05	0.000209	CcSEcCtD
Vandetanib—Vomiting—Mitoxantrone—prostate cancer	2.26e-05	0.000208	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—prostate cancer	2.25e-05	0.000208	CcSEcCtD
Vandetanib—Convulsion—Prednisone—prostate cancer	2.25e-05	0.000207	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—prostate cancer	2.25e-05	0.000207	CcSEcCtD
Vandetanib—Hypertension—Prednisone—prostate cancer	2.24e-05	0.000207	CcSEcCtD
Vandetanib—Rash—Mitoxantrone—prostate cancer	2.24e-05	0.000206	CcSEcCtD
Vandetanib—Dermatitis—Mitoxantrone—prostate cancer	2.24e-05	0.000206	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.24e-05	0.000206	CcSEcCtD
Vandetanib—Headache—Mitoxantrone—prostate cancer	2.23e-05	0.000205	CcSEcCtD
Vandetanib—Insomnia—Docetaxel—prostate cancer	2.22e-05	0.000205	CcSEcCtD
Vandetanib—Arthralgia—Prednisone—prostate cancer	2.21e-05	0.000204	CcSEcCtD
Vandetanib—Paraesthesia—Docetaxel—prostate cancer	2.2e-05	0.000203	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—prostate cancer	2.2e-05	0.000203	CcSEcCtD
Vandetanib—Anxiety—Prednisone—prostate cancer	2.2e-05	0.000203	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—prostate cancer	2.2e-05	0.000202	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.19e-05	0.000202	CcSEcCtD
Vandetanib—Dyspnoea—Docetaxel—prostate cancer	2.19e-05	0.000202	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—prostate cancer	2.18e-05	0.000201	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—prostate cancer	2.17e-05	0.0002	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.17e-05	0.0002	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—prostate cancer	2.16e-05	0.000199	CcSEcCtD
Vandetanib—Dyspepsia—Docetaxel—prostate cancer	2.16e-05	0.000199	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—prostate cancer	2.16e-05	0.000199	CcSEcCtD
Vandetanib—Insomnia—Capecitabine—prostate cancer	2.15e-05	0.000198	CcSEcCtD
Vandetanib—Paraesthesia—Capecitabine—prostate cancer	2.13e-05	0.000197	CcSEcCtD
Vandetanib—Decreased appetite—Docetaxel—prostate cancer	2.13e-05	0.000197	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—prostate cancer	2.13e-05	0.000196	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Docetaxel—prostate cancer	2.12e-05	0.000195	CcSEcCtD
Vandetanib—Asthenia—Etoposide—prostate cancer	2.12e-05	0.000195	CcSEcCtD
Vandetanib—Dyspnoea—Capecitabine—prostate cancer	2.12e-05	0.000195	CcSEcCtD
Vandetanib—Oedema—Prednisone—prostate cancer	2.12e-05	0.000195	CcSEcCtD
Vandetanib—Fatigue—Docetaxel—prostate cancer	2.12e-05	0.000195	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—prostate cancer	2.11e-05	0.000195	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—prostate cancer	2.11e-05	0.000195	CcSEcCtD
Vandetanib—Nausea—Mitoxantrone—prostate cancer	2.11e-05	0.000195	CcSEcCtD
Vandetanib—Infection—Prednisone—prostate cancer	2.1e-05	0.000194	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—prostate cancer	2.1e-05	0.000194	CcSEcCtD
Vandetanib—Pain—Docetaxel—prostate cancer	2.1e-05	0.000194	CcSEcCtD
Vandetanib—Constipation—Docetaxel—prostate cancer	2.1e-05	0.000194	CcSEcCtD
Vandetanib—Dyspepsia—Capecitabine—prostate cancer	2.09e-05	0.000193	CcSEcCtD
Vandetanib—Pruritus—Etoposide—prostate cancer	2.09e-05	0.000193	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—prostate cancer	2.08e-05	0.000192	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—prostate cancer	2.08e-05	0.000192	CcSEcCtD
Vandetanib—Nervous system disorder—Prednisone—prostate cancer	2.08e-05	0.000191	CcSEcCtD
Vandetanib—Decreased appetite—Capecitabine—prostate cancer	2.07e-05	0.000191	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—prostate cancer	2.06e-05	0.00019	CcSEcCtD
Vandetanib—Skin disorder—Prednisone—prostate cancer	2.06e-05	0.00019	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Capecitabine—prostate cancer	2.05e-05	0.000189	CcSEcCtD
Vandetanib—Fatigue—Capecitabine—prostate cancer	2.05e-05	0.000189	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—prostate cancer	2.04e-05	0.000188	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—prostate cancer	2.04e-05	0.000188	CcSEcCtD
Vandetanib—Pain—Capecitabine—prostate cancer	2.03e-05	0.000187	CcSEcCtD
Vandetanib—Constipation—Capecitabine—prostate cancer	2.03e-05	0.000187	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—prostate cancer	2.03e-05	0.000187	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—prostate cancer	2.02e-05	0.000186	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—prostate cancer	2.02e-05	0.000186	CcSEcCtD
Vandetanib—Gastrointestinal pain—Docetaxel—prostate cancer	2.01e-05	0.000185	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—prostate cancer	2e-05	0.000185	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—prostate cancer	1.99e-05	0.000183	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—prostate cancer	1.96e-05	0.00018	CcSEcCtD
Vandetanib—Dizziness—Etoposide—prostate cancer	1.95e-05	0.00018	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—prostate cancer	1.95e-05	0.00018	CcSEcCtD
Vandetanib—Gastrointestinal pain—Capecitabine—prostate cancer	1.94e-05	0.000179	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—prostate cancer	1.94e-05	0.000179	CcSEcCtD
Vandetanib—Body temperature increased—Docetaxel—prostate cancer	1.94e-05	0.000179	CcSEcCtD
Vandetanib—Abdominal pain—Docetaxel—prostate cancer	1.94e-05	0.000179	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Prednisone—prostate cancer	1.93e-05	0.000178	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—prostate cancer	1.93e-05	0.000178	CcSEcCtD
Vandetanib—Insomnia—Prednisone—prostate cancer	1.92e-05	0.000177	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—prostate cancer	1.91e-05	0.000176	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—prostate cancer	1.91e-05	0.000176	CcSEcCtD
Vandetanib—Paraesthesia—Prednisone—prostate cancer	1.9e-05	0.000175	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—prostate cancer	1.89e-05	0.000174	CcSEcCtD
Vandetanib—Abdominal pain—Capecitabine—prostate cancer	1.88e-05	0.000173	CcSEcCtD
Vandetanib—Body temperature increased—Capecitabine—prostate cancer	1.88e-05	0.000173	CcSEcCtD
Vandetanib—Vomiting—Etoposide—prostate cancer	1.88e-05	0.000173	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—prostate cancer	1.88e-05	0.000173	CcSEcCtD
Vandetanib—Dyspepsia—Prednisone—prostate cancer	1.86e-05	0.000172	CcSEcCtD
Vandetanib—Rash—Etoposide—prostate cancer	1.86e-05	0.000172	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—prostate cancer	1.86e-05	0.000172	CcSEcCtD
Vandetanib—Headache—Etoposide—prostate cancer	1.85e-05	0.000171	CcSEcCtD
Vandetanib—Decreased appetite—Prednisone—prostate cancer	1.84e-05	0.00017	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—prostate cancer	1.84e-05	0.00017	CcSEcCtD
Vandetanib—Fatigue—Prednisone—prostate cancer	1.83e-05	0.000168	CcSEcCtD
Vandetanib—Constipation—Prednisone—prostate cancer	1.81e-05	0.000167	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—prostate cancer	1.81e-05	0.000166	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—prostate cancer	1.78e-05	0.000164	CcSEcCtD
Vandetanib—Cough—Epirubicin—prostate cancer	1.77e-05	0.000163	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—prostate cancer	1.77e-05	0.000163	CcSEcCtD
Vandetanib—Asthenia—Docetaxel—prostate cancer	1.76e-05	0.000162	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—prostate cancer	1.76e-05	0.000162	CcSEcCtD
Vandetanib—Nausea—Etoposide—prostate cancer	1.75e-05	0.000162	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—prostate cancer	1.75e-05	0.000162	CcSEcCtD
Vandetanib—Pruritus—Docetaxel—prostate cancer	1.74e-05	0.00016	CcSEcCtD
Vandetanib—Gastrointestinal pain—Prednisone—prostate cancer	1.73e-05	0.00016	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—prostate cancer	1.73e-05	0.000159	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—prostate cancer	1.73e-05	0.000159	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—prostate cancer	1.72e-05	0.000159	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.72e-05	0.000158	CcSEcCtD
Vandetanib—Asthenia—Capecitabine—prostate cancer	1.71e-05	0.000157	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—prostate cancer	1.69e-05	0.000156	CcSEcCtD
Vandetanib—Pruritus—Capecitabine—prostate cancer	1.68e-05	0.000155	CcSEcCtD
Vandetanib—Diarrhoea—Docetaxel—prostate cancer	1.68e-05	0.000155	CcSEcCtD
Vandetanib—Abdominal pain—Prednisone—prostate cancer	1.67e-05	0.000154	CcSEcCtD
Vandetanib—Body temperature increased—Prednisone—prostate cancer	1.67e-05	0.000154	CcSEcCtD
Vandetanib—Oedema—Epirubicin—prostate cancer	1.66e-05	0.000153	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—prostate cancer	1.65e-05	0.000152	CcSEcCtD
Vandetanib—Infection—Epirubicin—prostate cancer	1.65e-05	0.000152	CcSEcCtD
Vandetanib—Cough—Doxorubicin—prostate cancer	1.64e-05	0.000151	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—prostate cancer	1.63e-05	0.00015	CcSEcCtD
Vandetanib—Diarrhoea—Capecitabine—prostate cancer	1.63e-05	0.00015	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—prostate cancer	1.62e-05	0.00015	CcSEcCtD
Vandetanib—Dizziness—Docetaxel—prostate cancer	1.62e-05	0.00015	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—prostate cancer	1.62e-05	0.00015	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—prostate cancer	1.62e-05	0.000149	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—prostate cancer	1.61e-05	0.000148	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—prostate cancer	1.6e-05	0.000147	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—prostate cancer	1.6e-05	0.000147	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—prostate cancer	1.59e-05	0.000147	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.59e-05	0.000146	CcSEcCtD
Vandetanib—Dizziness—Capecitabine—prostate cancer	1.57e-05	0.000145	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—prostate cancer	1.56e-05	0.000144	CcSEcCtD
Vandetanib—Vomiting—Docetaxel—prostate cancer	1.56e-05	0.000144	CcSEcCtD
Vandetanib—Rash—Docetaxel—prostate cancer	1.55e-05	0.000143	CcSEcCtD
Vandetanib—Dermatitis—Docetaxel—prostate cancer	1.55e-05	0.000143	CcSEcCtD
Vandetanib—Headache—Docetaxel—prostate cancer	1.54e-05	0.000142	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—prostate cancer	1.53e-05	0.000141	CcSEcCtD
Vandetanib—Infection—Doxorubicin—prostate cancer	1.52e-05	0.00014	CcSEcCtD
Vandetanib—Asthenia—Prednisone—prostate cancer	1.52e-05	0.00014	CcSEcCtD
Vandetanib—Vomiting—Capecitabine—prostate cancer	1.51e-05	0.000139	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.51e-05	0.000139	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—prostate cancer	1.5e-05	0.000139	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—prostate cancer	1.5e-05	0.000138	CcSEcCtD
Vandetanib—Rash—Capecitabine—prostate cancer	1.5e-05	0.000138	CcSEcCtD
Vandetanib—Pruritus—Prednisone—prostate cancer	1.5e-05	0.000138	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—prostate cancer	1.5e-05	0.000138	CcSEcCtD
Vandetanib—Dermatitis—Capecitabine—prostate cancer	1.5e-05	0.000138	CcSEcCtD
Vandetanib—Headache—Capecitabine—prostate cancer	1.49e-05	0.000137	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—prostate cancer	1.49e-05	0.000137	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—prostate cancer	1.49e-05	0.000137	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—prostate cancer	1.48e-05	0.000136	CcSEcCtD
Vandetanib—Nausea—Docetaxel—prostate cancer	1.46e-05	0.000134	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—prostate cancer	1.46e-05	0.000134	CcSEcCtD
Vandetanib—Diarrhoea—Prednisone—prostate cancer	1.45e-05	0.000134	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—prostate cancer	1.44e-05	0.000133	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—prostate cancer	1.43e-05	0.000132	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—prostate cancer	1.43e-05	0.000132	CcSEcCtD
Vandetanib—Constipation—Epirubicin—prostate cancer	1.42e-05	0.000131	CcSEcCtD
Vandetanib—Pain—Epirubicin—prostate cancer	1.42e-05	0.000131	CcSEcCtD
Vandetanib—Nausea—Capecitabine—prostate cancer	1.41e-05	0.00013	CcSEcCtD
Vandetanib—Dizziness—Prednisone—prostate cancer	1.4e-05	0.000129	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.4e-05	0.000129	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—prostate cancer	1.39e-05	0.000128	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—prostate cancer	1.38e-05	0.000127	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—prostate cancer	1.37e-05	0.000126	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—prostate cancer	1.35e-05	0.000125	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—prostate cancer	1.35e-05	0.000124	CcSEcCtD
Vandetanib—Vomiting—Prednisone—prostate cancer	1.35e-05	0.000124	CcSEcCtD
Vandetanib—Rash—Prednisone—prostate cancer	1.34e-05	0.000123	CcSEcCtD
Vandetanib—Dermatitis—Prednisone—prostate cancer	1.33e-05	0.000123	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—prostate cancer	1.33e-05	0.000123	CcSEcCtD
Vandetanib—Headache—Prednisone—prostate cancer	1.33e-05	0.000122	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.32e-05	0.000122	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—prostate cancer	1.32e-05	0.000122	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—prostate cancer	1.31e-05	0.000121	CcSEcCtD
Vandetanib—Pain—Doxorubicin—prostate cancer	1.31e-05	0.000121	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—prostate cancer	1.31e-05	0.000121	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—prostate cancer	1.31e-05	0.000121	CcSEcCtD
Vandetanib—VEGFA—Dexamethasone—Prednisone—prostate cancer	1.3e-05	0.00566	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Prednisone—prostate cancer	1.3e-05	0.00566	CbGdCrCtD
Vandetanib—Nausea—Prednisone—prostate cancer	1.26e-05	0.000116	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—prostate cancer	1.25e-05	0.000116	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—prostate cancer	1.21e-05	0.000112	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—prostate cancer	1.21e-05	0.000112	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—prostate cancer	1.19e-05	0.00011	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—prostate cancer	1.17e-05	0.000108	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—prostate cancer	1.13e-05	0.000104	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—prostate cancer	1.1e-05	0.000101	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—prostate cancer	1.1e-05	0.000101	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—prostate cancer	1.08e-05	0.0001	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—prostate cancer	1.05e-05	9.71e-05	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—prostate cancer	1.05e-05	9.67e-05	CcSEcCtD
Vandetanib—Rash—Epirubicin—prostate cancer	1.04e-05	9.63e-05	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—prostate cancer	1.04e-05	9.62e-05	CcSEcCtD
Vandetanib—Headache—Epirubicin—prostate cancer	1.04e-05	9.57e-05	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—prostate cancer	1.01e-05	9.34e-05	CcSEcCtD
Vandetanib—Nausea—Epirubicin—prostate cancer	9.84e-06	9.07e-05	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—prostate cancer	9.74e-06	8.98e-05	CcSEcCtD
Vandetanib—Rash—Doxorubicin—prostate cancer	9.66e-06	8.91e-05	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—prostate cancer	9.65e-06	8.9e-05	CcSEcCtD
Vandetanib—Headache—Doxorubicin—prostate cancer	9.6e-06	8.85e-05	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—prostate cancer	9.1e-06	8.39e-05	CcSEcCtD
Vandetanib—EGFR—Signaling Pathways—MDM2—prostate cancer	3.63e-07	3.03e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—prostate cancer	3.62e-07	3.03e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—prostate cancer	3.62e-07	3.03e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTT1—prostate cancer	3.62e-07	3.03e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ACHE—prostate cancer	3.62e-07	3.03e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—prostate cancer	3.62e-07	3.02e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—prostate cancer	3.61e-07	3.02e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—prostate cancer	3.61e-07	3.01e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—prostate cancer	3.6e-07	3.01e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—prostate cancer	3.6e-07	3.01e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1A—prostate cancer	3.59e-07	3e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—prostate cancer	3.59e-07	3e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—prostate cancer	3.58e-07	2.99e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JAK2—prostate cancer	3.58e-07	2.99e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.58e-07	2.99e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ERBB2—prostate cancer	3.58e-07	2.99e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—prostate cancer	3.56e-07	2.97e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—prostate cancer	3.55e-07	2.97e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—prostate cancer	3.55e-07	2.97e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—prostate cancer	3.55e-07	2.97e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EP300—prostate cancer	3.54e-07	2.96e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—prostate cancer	3.54e-07	2.96e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1A—prostate cancer	3.54e-07	2.96e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—prostate cancer	3.54e-07	2.96e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—prostate cancer	3.53e-07	2.95e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CB—prostate cancer	3.53e-07	2.95e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—prostate cancer	3.51e-07	2.94e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MDM2—prostate cancer	3.5e-07	2.92e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EP300—prostate cancer	3.49e-07	2.92e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—prostate cancer	3.49e-07	2.92e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—prostate cancer	3.49e-07	2.92e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CAV1—prostate cancer	3.48e-07	2.91e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.48e-07	2.91e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—prostate cancer	3.48e-07	2.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAP2K1—prostate cancer	3.48e-07	2.91e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—prostate cancer	3.46e-07	2.9e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PRKACB—prostate cancer	3.46e-07	2.9e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—prostate cancer	3.46e-07	2.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CD—prostate cancer	3.45e-07	2.89e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—prostate cancer	3.45e-07	2.88e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ERBB2—prostate cancer	3.45e-07	2.88e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.43e-07	2.87e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—prostate cancer	3.42e-07	2.86e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EP300—prostate cancer	3.42e-07	2.86e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—prostate cancer	3.42e-07	2.86e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—prostate cancer	3.41e-07	2.85e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—prostate cancer	3.41e-07	2.85e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—prostate cancer	3.4e-07	2.85e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CB—prostate cancer	3.4e-07	2.84e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—prostate cancer	3.4e-07	2.84e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—prostate cancer	3.4e-07	2.84e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—prostate cancer	3.39e-07	2.84e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—prostate cancer	3.39e-07	2.83e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EP300—prostate cancer	3.37e-07	2.81e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—prostate cancer	3.34e-07	2.8e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.33e-07	2.78e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—prostate cancer	3.33e-07	2.78e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—prostate cancer	3.32e-07	2.78e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—prostate cancer	3.32e-07	2.78e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1B—prostate cancer	3.31e-07	2.77e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—prostate cancer	3.31e-07	2.76e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF2—prostate cancer	3.31e-07	2.76e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—prostate cancer	3.28e-07	2.74e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—prostate cancer	3.27e-07	2.74e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—prostate cancer	3.27e-07	2.74e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—prostate cancer	3.27e-07	2.74e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—prostate cancer	3.27e-07	2.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—prostate cancer	3.27e-07	2.73e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—prostate cancer	3.27e-07	2.73e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NCOA2—prostate cancer	3.27e-07	2.73e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—prostate cancer	3.26e-07	2.73e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—prostate cancer	3.26e-07	2.73e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—prostate cancer	3.26e-07	2.72e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—EP300—prostate cancer	3.25e-07	2.71e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—prostate cancer	3.25e-07	2.71e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—prostate cancer	3.24e-07	2.71e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—prostate cancer	3.24e-07	2.71e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—prostate cancer	3.22e-07	2.7e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—prostate cancer	3.22e-07	2.69e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—prostate cancer	3.21e-07	2.68e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—prostate cancer	3.21e-07	2.68e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—prostate cancer	3.2e-07	2.67e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—prostate cancer	3.19e-07	2.67e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1B—prostate cancer	3.19e-07	2.67e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—prostate cancer	3.19e-07	2.66e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—prostate cancer	3.18e-07	2.66e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—prostate cancer	3.17e-07	2.65e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JAK2—prostate cancer	3.17e-07	2.65e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—prostate cancer	3.16e-07	2.64e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—prostate cancer	3.16e-07	2.64e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—prostate cancer	3.16e-07	2.64e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—prostate cancer	3.15e-07	2.63e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—prostate cancer	3.15e-07	2.63e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—prostate cancer	3.13e-07	2.62e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—prostate cancer	3.13e-07	2.61e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—prostate cancer	3.12e-07	2.61e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.12e-07	2.6e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—prostate cancer	3.11e-07	2.6e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MDM2—prostate cancer	3.09e-07	2.59e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—prostate cancer	3.09e-07	2.58e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—prostate cancer	3.09e-07	2.58e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—prostate cancer	3.08e-07	2.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—prostate cancer	3.07e-07	2.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—prostate cancer	3.07e-07	2.56e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—prostate cancer	3.06e-07	2.55e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ERBB2—prostate cancer	3.05e-07	2.55e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—prostate cancer	3.05e-07	2.55e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—prostate cancer	3.04e-07	2.55e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.04e-07	2.54e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—prostate cancer	3.04e-07	2.54e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—prostate cancer	3.04e-07	2.54e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—prostate cancer	3.02e-07	2.52e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—prostate cancer	3.01e-07	2.52e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—prostate cancer	3.01e-07	2.52e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CB—prostate cancer	3.01e-07	2.52e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NQO1—prostate cancer	3.01e-07	2.52e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—prostate cancer	3e-07	2.51e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—INS—prostate cancer	3e-07	2.51e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—prostate cancer	2.99e-07	2.5e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—prostate cancer	2.98e-07	2.49e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—prostate cancer	2.98e-07	2.49e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—prostate cancer	2.97e-07	2.49e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—prostate cancer	2.97e-07	2.48e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TH—prostate cancer	2.97e-07	2.48e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—prostate cancer	2.96e-07	2.47e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—prostate cancer	2.96e-07	2.47e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—prostate cancer	2.95e-07	2.46e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—prostate cancer	2.95e-07	2.46e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CREBBP—prostate cancer	2.94e-07	2.46e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—prostate cancer	2.94e-07	2.46e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—prostate cancer	2.93e-07	2.45e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—prostate cancer	2.93e-07	2.45e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—prostate cancer	2.91e-07	2.44e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EP300—prostate cancer	2.91e-07	2.43e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—prostate cancer	2.9e-07	2.43e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—prostate cancer	2.89e-07	2.42e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—prostate cancer	2.89e-07	2.41e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.89e-07	2.41e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—prostate cancer	2.87e-07	2.4e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—prostate cancer	2.87e-07	2.4e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—prostate cancer	2.85e-07	2.38e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—prostate cancer	2.84e-07	2.37e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—prostate cancer	2.84e-07	2.37e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—prostate cancer	2.83e-07	2.36e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1B—prostate cancer	2.83e-07	2.36e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—prostate cancer	2.81e-07	2.35e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EP300—prostate cancer	2.8e-07	2.34e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GGT1—prostate cancer	2.79e-07	2.34e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CD—prostate cancer	2.79e-07	2.33e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—prostate cancer	2.77e-07	2.32e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—prostate cancer	2.77e-07	2.31e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—prostate cancer	2.76e-07	2.31e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—prostate cancer	2.75e-07	2.3e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—prostate cancer	2.75e-07	2.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NCOA1—prostate cancer	2.75e-07	2.3e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—prostate cancer	2.73e-07	2.28e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—prostate cancer	2.73e-07	2.28e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—prostate cancer	2.73e-07	2.28e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—prostate cancer	2.72e-07	2.27e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—prostate cancer	2.72e-07	2.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.71e-07	2.27e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—prostate cancer	2.71e-07	2.27e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—prostate cancer	2.7e-07	2.25e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—prostate cancer	2.67e-07	2.23e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—prostate cancer	2.66e-07	2.23e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—prostate cancer	2.65e-07	2.22e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—prostate cancer	2.63e-07	2.2e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—prostate cancer	2.63e-07	2.2e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—prostate cancer	2.62e-07	2.19e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—prostate cancer	2.62e-07	2.19e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—prostate cancer	2.62e-07	2.19e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—RXRA—prostate cancer	2.62e-07	2.19e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—prostate cancer	2.62e-07	2.19e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—prostate cancer	2.61e-07	2.18e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—prostate cancer	2.6e-07	2.17e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—prostate cancer	2.58e-07	2.16e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—prostate cancer	2.53e-07	2.12e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—prostate cancer	2.53e-07	2.11e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—prostate cancer	2.53e-07	2.11e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—COMT—prostate cancer	2.52e-07	2.11e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—prostate cancer	2.51e-07	2.1e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—prostate cancer	2.51e-07	2.1e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—prostate cancer	2.51e-07	2.1e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—prostate cancer	2.5e-07	2.09e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—prostate cancer	2.49e-07	2.08e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EP300—prostate cancer	2.48e-07	2.07e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ITPR1—prostate cancer	2.47e-07	2.06e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—prostate cancer	2.45e-07	2.05e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—prostate cancer	2.44e-07	2.04e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—prostate cancer	2.44e-07	2.04e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CB—prostate cancer	2.43e-07	2.03e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—prostate cancer	2.42e-07	2.02e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—prostate cancer	2.41e-07	2.01e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—prostate cancer	2.41e-07	2.01e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—prostate cancer	2.4e-07	2.01e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—prostate cancer	2.39e-07	2e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—prostate cancer	2.35e-07	1.96e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—prostate cancer	2.34e-07	1.96e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TYMS—prostate cancer	2.33e-07	1.95e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—prostate cancer	2.33e-07	1.94e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—prostate cancer	2.32e-07	1.94e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—prostate cancer	2.32e-07	1.94e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—prostate cancer	2.31e-07	1.93e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—prostate cancer	2.29e-07	1.91e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPL—prostate cancer	2.26e-07	1.89e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—prostate cancer	2.26e-07	1.89e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—prostate cancer	2.24e-07	1.87e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—prostate cancer	2.23e-07	1.86e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—prostate cancer	2.2e-07	1.84e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.19e-07	1.83e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ERCC2—prostate cancer	2.17e-07	1.81e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—prostate cancer	2.16e-07	1.81e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—prostate cancer	2.16e-07	1.8e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—prostate cancer	2.15e-07	1.8e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—prostate cancer	2.14e-07	1.79e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—prostate cancer	2.11e-07	1.77e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—prostate cancer	2.11e-07	1.76e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—prostate cancer	2.1e-07	1.76e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—prostate cancer	2.08e-07	1.74e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—prostate cancer	2.07e-07	1.73e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—prostate cancer	2.07e-07	1.73e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—prostate cancer	2.04e-07	1.7e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—prostate cancer	2.03e-07	1.7e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—prostate cancer	2.01e-07	1.68e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—EP300—prostate cancer	2e-07	1.67e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARA—prostate cancer	2e-07	1.67e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—prostate cancer	2e-07	1.67e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—prostate cancer	1.96e-07	1.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—prostate cancer	1.9e-07	1.59e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAV1—prostate cancer	1.88e-07	1.57e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—prostate cancer	1.84e-07	1.53e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—prostate cancer	1.84e-07	1.53e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—prostate cancer	1.78e-07	1.48e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—prostate cancer	1.76e-07	1.47e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.71e-07	1.43e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—prostate cancer	1.69e-07	1.42e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—prostate cancer	1.63e-07	1.36e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—INS—prostate cancer	1.62e-07	1.36e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CREBBP—prostate cancer	1.59e-07	1.33e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.51e-07	1.26e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—prostate cancer	1.5e-07	1.25e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—prostate cancer	1.48e-07	1.24e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—prostate cancer	1.42e-07	1.19e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.31e-07	1.1e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—prostate cancer	1.3e-07	1.09e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—prostate cancer	1.21e-07	1.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—prostate cancer	1.13e-07	9.48e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—EP300—prostate cancer	1.08e-07	9.04e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—prostate cancer	8e-08	6.69e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—prostate cancer	6.54e-08	5.46e-07	CbGpPWpGaD
